LRRK2-targeting therapies for Parkinson’s disease

Mutations in the LRRK2 gene are among the most common genetic contributors to Parkinson’s disease and represent a promising target for disease-modifying therapies. Our lab is actively engaged in two sponsored clinical trials evaluating BIIB122 (DNL151), a selective LRRK2 inhibitor, in Parkinson’s patients:

• LUMA (NCT05348785) is a Phase 2b, double-blind, placebo-controlled trial in early-stage Parkinson’s disease (with or without LRRK2 mutations) to assess the safety, tolerability, and potential to slow disease progression.

  • https://pubmed.ncbi.nlm.nih.gov/36807624/

• BEACON (NCT06602193) is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study (12 weeks plus extension) focused specifically on participants with genetically confirmed LRRK2-PD, to measure pharmacodynamic effects, biomarker engagement, and safety.